TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Primary HLH patients with active disease.~* Treatment naïve patients or patients having already received HLH conventional therapy, but having not responded, not achieved a satisfactory response or worsened, or reactivated, or are unable to tolerate current standard of care.~* Informed consent signed by the patient or by the patient's legally authorized representative.~* Received guidance on contraception.~Main Exclusion Criteria:~* Diagnosis of secondary HLH consequent to a proven rheumatic, metabolic or neoplastic disease.~* Active mycobacteria, Histoplasma capsulatum, Shigella, Salmonella, Campylobacter or Leishmania infections.~* Evidence of latent tuberculosis.~* Presence of malignancy.~* Concomitant disease or malformation severely affecting cardiovascular, pulmonary, central nervous system (CNS), liver, or renal function, that in the opinion of the Investigator may significantly affect the likelihood to respond to treatment and/or the assessment of emapalumab safety and/or efficacy.~* History of hypersensitivity or allergy to any component of the study regimen.~* Receipt of a BCG vaccine within 12 weeks prior to Screening.~* Receipt of a live or attenuated-live (other than BCG) vaccine within 6 weeks prior to Screening.~* Pregnant or lactating female patients.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Emapalumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Currently treated with insulin~* Currently treated with Metformin~* HbA1c: 7.5-12.0%~Exclusion Criteria:~* Body Mass Index (BMI) \< 25.0 or \> 40.0 kg/m2~* Metformin contraindications according to local practice~* TZDs within 6 months prior to randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefits of Assistive Listening Device for Speech Intelligibility

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adults age 18 or older with bilateral moderate to moderate severe sensorineural hearing loss, pure tone average must be between 40 and 69 dB HL (decibel Hearing Level)~* experienced hearing aid users~* symmetric hearing loss (no more than 15 dB difference between the ears at three contiguous frequencies)~* good written and spoken English language skills~* healthy outer ear as confirmed by otoscopy~Exclusion Criteria:~* contradictions to medical device noted upon otoscopy~* known hypersensitivity or allergy to materials of investigational device or comparator~* inability to produce reliable test results~* known psychological problems~* self reported symptoms of dizziness or vertigo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Participants with bilateral moderate to severe sensorineural hearing loss

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Study of Rectus Muscle Closure at Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~37 weeks gestation Primary cesarean American Society of Anesthesiologists (ASA) class 1 or class 2~Exclusion Criteria:~Chronic analgesia use Vertical skin incision at cesarean Opioid or Non-steroidal anti-inflammatory drugs (NSAID) allergy BMI \>40 Labor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rectus muscle closure (Type: ACTIVE_COMPARATOR): Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
- Rectus muscle non-closure (Type: NO_INTERVENTION): Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be eligible for study enrollment if they: are adolescents between the ages of 13 and 17 years~* have a confirmed diagnosis of schizophrenia and are suffering from an acute episode~* provide their assent and parental informed consent to participate~* are otherwise relatively healthy on the basis of a medical and physical examination~* and are able to be in-patients for approximately 2 weeks.~Exclusion Criteria:~* Subjects will be excluded from the study if they: meet the criteria for psychiatric disorders other than schizophrenia~* have moderate or severe mental retardation~* fail to respond to treatment with at least two typical or atypical antipsychotics~* have a history of substance dependence within the 3 months before screening~* are considered at risk for suicidal or violent behavior~* have a seizure disorder~* have a history of neuroleptic malignant syndrome, similar encephalopathic syndrome, or tardive dyskinesia~* or receive prohibited medication within a specified period before screening.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Nilotinib in CML-CP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 19 or older~* Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase~Exclusion Criteria:~* CML with atypical BCR-ABL1 transcripts (transcripts other than e13a2 or e14a2)~* Eastern Cooperative Oncology Group performance status ≥ 3~* Cardiac abnormality including a corrected QT interval ≥ 480 milliseconds, complete left bundle branch block, permanent pacemaker implantation, congenital long QT syndrome, history of tachyarrhythmia requiring treatment, clinically significant resting bradycardia, history of acute coronary syndrome within 12 months, and decompensated congestive heart failure~* Organ dysfunction defined by total serum bilirubin levels ≥ 1.5 × the upper limit of the normal range (ULN), creatinine ≥ 1.5 × ULN, aspartate or alanine aminotransferase ≥ 2.5 × ULN, amylase or lipase ≥ 1.5 × ULN and alkaline phosphatase ≥ 2.5 × ULN not directly related to the CML~* Uncontrolled hypertension and/or diabetes~* Active and uncontrolled infection~* Major surgery within two weeks or incomplete recovery from the previous surgery~* Congenital or acquired bleeding tendency~* Impaired gastrointestinal absorption~* History of small bowel resection or bypass surgery~* History of acute pancreatitis within 12 months or chronic pancreatitis~* Concomitant administration of strong irreplaceable CYP3A4 inhibitors or inducers, QT-prolonging agents, or coumarin derivatives~* Any other uncontrolled medical conditions that would present substantial safety risks or compromise compliance with the study treatment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational arm (Type: EXPERIMENTAL): Oral nilotinib 300mg twice daily with a 12-hour interval

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is highly unlikely to conceive~* Patient meets one of the 3 categories is naïve to all antihyperglycemic agent (AHA) therapies, or is non-naïve based upon the patient's current diet, medical regimen and screening A1c patient is currently not on AHA with a screening A1c \>=7.5 % and =\<11.0 % patient is currently on either metformin pr sulfonylurea monotherapy with a screening A1c \>=7.0 % and =\<9.0 %~Exclusion Criteria~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has C=peptide value of =\<0.8 ng/mL~* Patient has previously been treated with insulin, thiazolidinedione (TZD) (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a clinical study with any DPP-4 inhibitor or incretin mimetic~* Patient is on a weight loss program and is not in the maintenance phase or has started a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks~* Patient has undergone surgery within the prior 30 days or has major surgery planned during the study~* Patient has a medical history of active liver disease including chronic active hepatitis B or C or symptomatic gallbladder disease including primary biliary cirrhosis~* Patient has received treatment with an investigational product within 12 weeks prior to Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: EXPERIMENTAL): None
- Pioglitazone 15 mg (Type: EXPERIMENTAL): None
- Pioglitazone 30 mg (Type: EXPERIMENTAL): None
- Pioglitazone 45 mg (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg/ Pioglitazone 15 mg (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg/ Pioglitazone 30 mg (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg/ Pioglitazone 45 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed neoplasm~* 18 years of age or older~* Have received opioids for analgesia for at least 2 weeks and been on a stable regimen of opioids and laxatives for 3 or more days before study entry~* Fewer than three laxation during the preceding week and no laxation within 24 hours before study entry, or no laxation within 48 hours before study entry~* Life expectancy of at least 6 months~* World Health Organization Performance Status 0-3~* Women of childbearing potential must have a negative pregnancy test~* Breastfeeding should be discontinued prior to study entry~* Ability to understand and the willingness to sign a written informed consent document.~* Laboratory values within a week of study entry:~Absolute neutrophil count \> 1,500/microliter Hemoglobin \> 7 g/dL Platelet count \> 100,000/microliter Calculated calcium \< 10.5 mg/dL Calculated creatinine clearance \> 30 mg.min Alanine aminotransferase \< 3 x upper limit of normal (ULN) Aspartate aminotransferase \< 3 x ULN Alkaline phosphatase \< 2.5 x ULN Bilirubin \< 1.5 x ULN~Exclusion Criteria:~* Constipation not primarily caused by opioids, such as mechanical gastrointestinal obstruction or ongoing vinca alkaloid administration~* Indwelling peritoneal catheter~* Clinically active diverticular disease~* Fecal impaction~* Acute surgical abdomen~* Fecal ostomy~* Peritoneal carcinomatosis~* Known hypersensitivity to methylnaltrexone, naltrexone, or naloxone~* Administration of any investigational drug or experimental product within the previous 30 days~* Initiation of a new bowel regimen or prokinetic agents within a week of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylnaltrexone bromide (Type: EXPERIMENTAL): A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing of a Valsalva Assist Device (VAD) in Healthy Volunteers Performing a Valsalva Manoeuvre

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult Volunteers between 18 and 60 years old from University of Exeter or RD\&E Hospital staff~* Sinus rhythm on initial ECG~* Self-reported good health~Exclusion Criteria:~* Any regular medication other than the oral contraceptive~* Previous cardiovascular or respiratory disease~* Any contraindication to performing a VM strain. (Eg. Known aortic stenosis, recent myocardial infarction, glaucoma, retinopathy)~* Pregnancy~* Any ECG abnormality~* Any contra-indication to postural modification (any reason the participant can't lie flat and have both legs lifted to 45 degrees, eg prosthetic hip~* Inability or refusal to give written consent to take part~* Observations of heart rate, oxygen saturations, respiratory rate or blood pressure outside the normal range. Specifically blood pressure less than 100 systolic~* Caffeinated drinks within 6 hours prior to testing~* The use of stimulant drugs or alcohol within 24 hours prior to testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Four VM's (Type: OTHER): Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glyceryl Trinitrate Versus Lidocaine Cream for IUD Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Women not taken analgesics or anxiolytics in the 24 hours prior insertion~2. Women not taken misoprostol prior to IUD insertion~3. No contraindication to or history of allergic reaction to lidocaine or NO donors.~4. Women who will accept to participate in the study~Exclusion criteria:~1. Lidocaine allergy~2. History of migraine or chronic headache~3. Any contraindication to IUD placement

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- glyceryl trinitrate cream (Type: EXPERIMENTAL): The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL glyceryl trinitrate cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
- lidocaine cream (Type: EXPERIMENTAL): The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
- placebo cream (Type: PLACEBO_COMPARATOR): The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine.1 mL placebo cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Educational Intervention to Improve HPV Vaccination Decision Quality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Parents of an adolescent between the ages of 9-17~2. A young adult patient between the ages of 18-26~3. Adolescent/young adult who has not yet received all three doses of the HPV vaccine.~4. Parent/young adult who can read and converse in either English or Spanish~Exclusion Criteria:~1. Age \<18,~2. Prisoners~3. Decisionally challenged subjects~4. Those who cannot read and converse in either English or Spanish~5. Those who have received all 3 doses of the HPV vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Tailored Intervention (Type: EXPERIMENTAL): Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
- Untailored Intervention (Type: OTHER): Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
- Usual Care (Type: OTHER): Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension stage II~* Male and female patients~* Age \>= 18 years old~Exclusion Criteria:~* Severe hypertension (systolic BP \>= 180 mmHg, diastolic BP \>= 110 mmHg~* Poorly controlled diabetes mellitus or type 1 DM~* History of myocardial infarction, stroke~* Presence of heart failure~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non responder Olmesartan/Amlodipine (Type: EXPERIMENTAL): Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel Blood Test to Predict Safe Foods for Infants and Toddlers With Food Protein-induced Enterocolitis Syndrome (FPIES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of FPIES~* Have to have documented reactions to 2-3 trigger foods with recurrent delayed vomiting or documented reactions to 4 or more trigger foods with recurrent delayed vomiting.~Exclusion Criteria:~* Patients who are currently on medications that suppress the immune system~* Patients who do not have at least 2 trigger foods identified.~* Patients who have a history of an organic Gastrointestinal (GI) disease (e.g., inflammatory bowel disease, celiac disease, biliary disorders, bowel resection), cardiac, pulmonary, neurologic, renal, endocrine, or gynecological pathology~* Lack of parental or guardian informed consent.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Blood test with assays (Type: EXPERIMENTAL): 10 participants with FPIES exhibiting reactions to more than 2 foods will be recruited.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented metastatic renal cell cancer with a component of clear cell histology.~* Evidence of measurable disease.~* Patients with mRCC must have received no prior systemic first-line therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.~Exclusion Criteria:~* Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy.~* Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete